Search for a trial

A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab

Objectives:Phase 1b: To determine the maximum tolerated dose (MTD) (up to 8mg/kg/day) through safety and tolerability of multiple doses of AMG 951 administered by intravenous (IV) infusion to subjects with NSCLC in combination with chemotherapy and…

Determination of the predictive value of FDG-PET-CT scans, blood proteins and blood cells for the prognosis for patients with lung cancer receiving concurrent chemo-radiation

The objective of this study is to investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with lung cancer during and after concurrent radiotherapy and chemotherapy.

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIb with effusion and stage IV Non-Small Cell Lung Cancer (NSCLC)

The objective of this phase III study is to compare the efficacy of sorafenib in combination with gemcitabine and cisplatin versus placebo with gemcitabine and cisplatin for first-line treatment of patients with stage IIIB (with effusion) or Stage…

Phase I study of concurrent with involved-field thoracic radiotherapy for inoperable non-squamous cell lung cancer, followed by both concurrent and maintenance Bevacizumab

Primary objectivesTo establish the safety and tolerability of1. two doses of bevacizumab 7.5 mg/kg administered every 3 weeks with concurrent thoracic radiotherapy to 66 Gy;2. concurrent (7.5 mg/kg) and maintenance (15 mg/kg) bevacizumab during, and…

Adaptive Image-Guided Radiotherapy (IGRT) for lung cancer using repeat treatment planning CT scan and PET-CT scans.

To establish the proportion of patients in whom an initial radiotherapy plan does not provide similar, or improved coverage, on a repeat planning procedure after 15 fractions. To implement adaptive radiotherapy.

Lobectomy for the treatment of non-small cell lung cancer (NSCLC):
video-assisted minithoracotomy (VAMT) versus muscle-sparing thoracotomy (MST)

see K1

'A one-day diagnostic track for lung cancer suspects from chest X-ray using PET-CT and subsequent multiple endoscopic investigations. (including bronchoscopy, EUS-FNA and EBUS-TBNA)'.

1. to study feasibility of a fast one-day diagnostic track including PET-CT and subsequent diagnostic/ staging investigation depending on PET-CT findings. to determine:2. the percentage of patients in which the one-day track is sufficient for…

Prospective study on cost-effectiveness of the Provox®2 and the Groningen Ultra Low Resistance tracheoesophageal shunt prostheses in voice rehabilitation of post-laryngectomy patients.

The objective of the study is a prospective study to evaluate which type of TE shunt prosthesis is the most cost-effective.

A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer

The primary objective of the Phase 2 portion of the study is to assess if the addition of ABT-751 at the RPTD to standard pemetrexed can prolong PFS compared to pemetrexed alone in subjects with advanced or metastatic NSCLC.

A study of respiratory waveforms derived using up to three motion monitoring systems in 4D radiotherapy planning and delivery

To compare respiratory waveforms generated using reflective markers located on the upper abdominal wall (the currently used Varian RPM system) with either magnetic sensors, belt sensors or both placed on the chest wall and/or upper abdomen. The…

'Comparison of EUS/EBUS-guided fine needle aspiration and PET-CT in the restaging after induction therapy of locally advanced non-small cell lung cancer'.

1. This study aims to compare the accuracy of EUS/EBUS and PET-CT as restaging tools in patients treated with induction therapy for stage IIIA or IIIB NSCLC.2. To study the additive value of immune histochemical staining of adequate biopsies…